



IMAGION BIOSYSTEMS LIMITED

APPENDIX 4D

FOR THE HALF-YEAR ENDED 30 JUNE 2023

1. Reporting period (“current period”): Half-year ended 30 June 2023
 Previous corresponding periods: Half-year ended 30 June 2022
 Year ended 31 December 2022

2. Results for announcement to the market

Item		Movement	\$AUD
Revenue	Up	159.6% to	690,012
(Loss) from ordinary activities after tax attributable to members	Up	33.4% to	(7,683,076)
Net (loss) for the period attributable to members	Up	42.2% to	(7,640,921)

Dividends

There were no dividends paid, recommended or declared during the current period.

3. Consolidated Statement of Profit and Loss and Other Comprehensive Income

Refer to the attached Financial Statements together with notes for the half-year ended 30 June 2023.

4. Consolidated Statement of Financial Position

Refer to the attached Financial Statements together with notes for the half-year ended 30 June 2023.

5. Consolidated Statement of Cash Flows

Refer to the attached Financial Statements together with notes for the half-year ended 30 June 2023.

6. Consolidated Statement of Changes in Equity

Refer to the attached Financial Statements together with notes for the half-year ended 30 June 2023.

7. Dividends

Current period:

There were no dividends paid, recommended or declared during the period.

Previous period:

There were no dividends paid, recommended or declared during the previous financial period.

8. Dividend reinvestment plans

There are no dividend reinvestment plans operation.

9. Net tangible assets

	30 Jun 2023 \$AUD	31 Dec 2022 \$AUD
Net tangible asset backing per ordinary share	(0.0014)	0.0042

10. Details of entities over which control has been gained or lost

N/A

11. Details of associates and joint venture entities

N/A

12. Any other significant information

N/A

13. Foreign Entities

Details of origin of Accounting Standards of foreign subsidiary:

Imagion Biosystems Limited owns 100% of Imagion Biosystems Inc. This company prepares their financial statements in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

14. Results for the period

Refer to the Review of Operations contained within the attached Imagion Biosystems Limited Half-Year Financial Report for the half-year ended 30 June 2023.

15. Status of Review

The Half-Year Financial Report has been independently reviewed.

16. Description of any likely review dispute or qualification:

The Half-Year Financial Report is not subject to a qualified independent review statement.